

Association of FEF_{25–75%} Impairment with Bronchial Hyperresponsiveness and Airway Inflammation in Subjects with Asthma-Like Symptoms

Mario Malerba^a Alessandro Radaeli^b Alessia Olivini^a Giovanni Damiani^a
Beatrice Ragnoli^b Valentina Sorbello^c Fabio L.M. Ricciardolo^c

^aDepartment of Internal Medicine, University of Brescia, Spedali Civili di Brescia, and

^bEmergency Department, Spedali Civili di Brescia, Brescia, and ^cDepartment of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Orbassano, Italy

Key Words

Forced expiratory flow at 25 and 75% of the pulmonary volume · Fractional exhaled nitric oxide · Bronchial asthma · Sputum eosinophilia · Bronchial hyperresponsiveness

Abstract

Background: Forced expiratory flow at 25 and 75% of the pulmonary volume (FEF_{25–75%}) might be considered as a marker of early airway obstruction. FEF_{25–75%} impairment might suggest earlier asthma recognition in symptomatic subjects even in the absence of other abnormal spirometry values. **Objectives:** The study was designed in order to verify whether FEF_{25–75%} impairment in a cohort of subjects with asthma-like symptoms could be associated with the risk of bronchial hyperresponsiveness (BHR) and with airway inflammation expressed as fractional exhaled nitric oxide (FeNO) and eosinophil counts in induced sputum. **Methods:** Four hundred adults with a history of asthma-like symptoms (10.5% allergic) underwent spirometry, determination of BHR to methacholine (PD₂₀FEV₁), FeNO analysis and sputum induction. FEF_{25–75%} <65% of predicted or <–1.64 z-score was considered abnormal. **Results:** All subjects had normal FVC, FEV₁ and FEV₁/FVC, while FEF_{25–75%} was abnormal in

27.5% of them. FEF_{25–75%} (z-score) was associated with PD₂₀FEV₁ (p < 0.001), FeNO (p < 0.001) and sputum eosinophils (p < 0.001). Patients with abnormal FEF_{25–75%} showed higher levels of FeNO and eosinophils in induced sputum than did patients with normal FEF_{25–75%} (p < 0.01 and p < 0.01, respectively). Subjects with abnormal FEF_{25–75%} had an increased probability of being BHR positive (OR = 13.38; 95% CI: 6.7–26.7; p < 0.001). **Conclusions:** Our data show that abnormal FEF_{25–75%} might be considered an early marker of air-flow limitation associated with eosinophilic inflammation and BHR in subjects with asthma-like symptoms, indicating a role for FEF_{25–75%} as a predictive marker of newly diagnosed asthma.

© 2016 S. Karger AG, Basel

Introduction

Small airways seem to be involved in asthma pathogenesis [1, 2]. Recently, according to this idea, Perez et al. [3] demonstrated that, among moderate-to-severe asthmatics, patients with only small airway obstruction (compared to those with proximal airway obstruction) showed no correlations between small airway obstruction and

asthma history, scores of dyspnoea, asthma control or drug compliance. These conclusions would imply an underestimation, in treated asthmatic patients, of small airway dysfunction in routinely used lung function testing [3]. Forced expiratory flow at 25 and 75% of the pulmonary volume ($FEF_{25-75\%}$) is defined as the mean forced expiratory flow during the middle half of the FVC and measures average flow rates on an FVC segment that includes flow from medium-to-small airways [4]. $FEF_{25-75\%}$ indicates the status of the medium-sized and small airways particularly in subjects with normal FEV_1 and FEV_1/FVC [4, 5]. $FEF_{25-75\%}$ varies significantly in healthy subjects and is considered abnormal when it reaches values <65% of predicted [6–8]. Muñoz-López et al. [9] pointed out that $FEF_{25-75\%}$ is more appropriate than FEV_1 for evaluating bronchial hyperresponsiveness (BHR) to methacholine and for indicating small airway impairment earlier in subjects with asthma and/or allergic rhinitis. Compromised $FEF_{25-75\%}$ has been associated with BHR in patients with allergic rhinitis [10] and in subjects with respiratory symptoms suggestive of bronchial asthma [11]. BHR is the hallmark of bronchial asthma, and in particular BHR to indirect stimuli is related to the degree of airway inflammation (especially eosinophilic infiltration) [12]. Furthermore, in children with allergic rhinitis/asthma, abnormal $FEF_{25-75\%}$ has been associated with elevated levels of fractional exhaled nitric oxide (FeNO) [13], which is primarily derived from the respiratory epithelium and seems to reflect eosinophilic airway inflammation [14]. FeNO measurement is a highly reproducible, safe, sensible, simple and rapid test [15–17]. Ciprandi et al. [18] demonstrated a strong and negative correlation between FeNO and BHR in asthmatic children; these results confirmed the existence of a link between airway inflammation and BHR. Tossa et al. [19] as well proved that an increased FeNO level was associated with BHR among apprentices.

The aim of our study was to verify whether abnormal $FEF_{25-75\%}$ in a cohort of subjects with asthma-like symptoms and normal FEV_1 and FEV_1/FVC could be associated with BHR and the degree of airway inflammation.

Subjects and Methods

Patients

From November 2011 to November 2013, 400 consecutive adult patients referred to the Respiratory Medicine Unit of the Department of Internal Medicine, University of Brescia, were studied in an outpatient setting. The patients complained of symptoms consistent with bronchial asthma: cough, chest tightness, dys-

pnoea or wheezing with nocturnal awakenings for >3 weeks with a normal chest X-ray and spirometry (FVC, FEV_1 and FEV_1/FVC) [20]. The exclusion criteria were use of any medication for cough, upper respiratory infection during the previous 6 weeks, use of corticosteroids during the previous 6 weeks, current smoking, any significant medical condition, a prior asthma diagnosis and the usual contraindications to methacholine challenge tests. The study was approved by the local ethics committee, and all participants provided written informed consent.

Recruited patients underwent the following procedures: clinical examination; symptom evaluation; skin prick testing; pulmonary function tests; determination of BHR to methacholine (methacholine challenge test); FeNO analysis; sputum induction, and eosinophil count.

Skin Prick Test

Allergy was assessed by skin prick test positivity to the most common aeroallergens as stated by the European Academy of Allergy and Clinical Immunology [21].

Pulmonary Function Tests

Spirometry and maximal full flow-volume curves were obtained using a pneumotachograph with a volume integrator (CAD/Net system 1070; Medical Graphics Corporation, St. Paul, Minn., USA). The pulmonary function tests were performed following American Thoracic Society criteria [22]. All indices (FVC, FEV_1 , FEV_1/FVC and $FEF_{25-75\%}$) were expressed as percent of predicted normal and z-scores. Predicted values and z-scores for the various indices were derived using prediction equations from the Global Lung Function Initiative (GLI-2012; <http://www.lungfunction.org/>) [23]. In particular, $FEF_{25-75\%}$ was categorized as (1) <65% of predicted or <-1.64 z-score (abnormal values) or (2) >65% of predicted or between -1.64 and +1.64 z-score (normal values) [23]. $FEF_{25-75\%}$ categorization by both criteria (% predicted and z-score) gave equal results. Only baseline or pre-bronchodilator data were analysed in the study.

Bronchial Hyperresponsiveness

The methacholine challenge test was performed according to international guidelines as a dose-response curve by increasing (doubling) doses of methacholine chlorohydrate every 3 min. Results were expressed as cumulative doses of methacholine provoking a 20% fall in FEV_1 (PD_{20}). A methacholine challenge test result was considered positive if the PD_{20} was <16.00 mg/ml [24].

Fractional Exhaled Nitric Oxide

FeNO was determined with a high-resolution chemiluminescence NO analyser (Ecomedics AG Analyzer CLD88; Dürnten, Switzerland), whose limit of detection was 0.06 ppb, with a measurement range reaching 100 ppb. The measurements were performed in accordance with the ATS recommendations using a standardized procedure for on-line measurement of exhaled NO in adults [25]. FeNO values between 4 and 20 ppb were considered within normal limits according to literature consensus, identifying 20 ppb as the cut-off point for a positive result [26].

Sputum Induction

After baseline FEV_1 and FVC measurements, the subjects were pre-treated with inhaled salbutamol (200 µg by metred-dose inhaler) and 10 min later inhaled a hypertonic (4.5%) nebulized ster-

ile saline solution for 3 periods of 5 min at most by means of an ultrasonic nebulizer (Ultraneb 2000; DeVilbiss, Somerset, Pa., USA). Nebulization was discontinued if one of the following symptoms occurred: wheezing, chest tightness or moderate-to-severe dyspnoea. Sputum was processed as previously reported [27]. The cut-off for an abnormal result was considered a sputum eosinophil count >3% (percentage of cells) [28].

Statistical Analysis

Values are expressed as medians (minimum–maximum) for continuous variables and as numbers and percentages for categorical variables. Spearman's rank method was applied if variables were not normally distributed. In order to obtain reliable assessments of the relationship between FEF_{25–75%} and the other variables, FEF_{25–75%} was considered both a continuous and a categorical variable.

BHR was categorized as 'negative' (threshold ≥ 16.0 mg/ml) or 'positive' (threshold <16.0 mg/ml) [24]. The χ^2 test was used to test the analysed categorical variables. The Mann-Whitney test was used to assess differences between categorical and continuous variables. OR for an effect of FEF_{25–75%} on BHR and relative 95% CI are shown. A p value ≤ 0.05 was considered statistically significant, and SPSS version 21 (IBM Corp., Armonk, N.Y., USA) was used for analysis.

The statistical power of the study was assessed with the PS Power and Sample Size program available for free on the Internet (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>). Concerning BHR, the study had a power of 96% with an OR difference of 3.5 in discriminating between abnormal and normal FEF_{25–75%} groups.

Results

Demographic, functional and biological patient characteristics are shown in table 1; the numbers of males and females were equally balanced, and patients were ex-smokers or non-smokers, with respiratory symptoms during the previous 6 months (symptoms might have been absent at the time of enrolment). Forty-two patients (10.5%) were sensitized to perennial and/or pollen allergens. Concerning spirometric parameters, in all subjects FVC, FEV₁ and FEV₁/FVC were within normal reference ranges, while FEF_{25–75%} was abnormal in 27.5% of the subjects, as extrapolated by percent of predicted or z-score data (a comparison of the data between subjects with normal and those with abnormal FEF_{25–75%} is shown in table 2). The median value of FeNO was 34.2 ppb (12–80), and the median sputum eosinophil count was 4.32 cells (0.0–21.0); 176 patients (42.0%) were negative to BHR (table 1). No significant differences in demographic or functional and biological data were observed when grouping patients according to gender, age, atopy or smoking habit.

Table 1. Patients' demographic, functional and biological characteristics

Age, years	29.6 (17.8–41.4)
Gender F/M	226/174 (56.5/43.5)
Smoking	
Non-smoker	323 (80.75)
Ex-smoker	77 (19.25)
Current smoker	0 (0)
Pack-years	2.7 (0–3.2)
Allergy	42 (10.5)
FVC, % predicted	106.99 (81.8–120.7)
FEV ₁ , % predicted	104.38 (82.6–116.5)
FEF _{25–75%} , % predicted	93.55 (20.0–190.0)
FEF _{25–75%} (z-score) [range]	–0.398 (1.66) [–4.54–3.48]
FEF _{25–75%} category (by % predicted or z-score)	
Normal	290 (72.5)
Abnormal	110 (27.5)
BHR, mg/ml	14.10 (0.10–16.00)
BHR category	
Negative (>16 mg/ml)	176 (44.0)
Positive (<16 mg/ml)	224 (56.0)
FeNO, ppb	34.21 (12–80)
Sputum eosinophils, %	4.32 (0.00–21.01)

Data are expressed as medians (minimum–maximum) or n (%) unless indicated otherwise.

A significant moderate positive correlation between BHR (expressed as PD₂₀FEV₁ to methacholine) and FEF_{25–75%} z-score (Spearman's coefficient = 0.339, p < 0.001; fig. 1) and percent of predicted (table 3) was noted, despite the wide scattering of data due to the large sample size. Significant strong negative correlations were observed between FEF_{25–75%} (z-score) and both FeNO (fig. 2; table 3) and sputum eosinophil count (fig. 3; table 3) (Spearman's coefficient = –0.729, p < 0.001, and Spearman's coefficient = –0.813, p < 0.001, respectively) as well as between BHR and both FeNO (Spearman's coefficient = –0.851, p < 0.001; fig. 4; table 3) and sputum eosinophil count (Spearman's coefficient = –0.760, p < 0.001; table 2). Finally, a strong positive correlation was found between FeNO and sputum eosinophil count (Spearman's coefficient = –0.944, p < 0.001; table 3).

Patients with positive BHR had a median FeNO value of 46.3 ppb (12–80); this result was significantly different (p < 0.001) from that of BHR-negative patients, who showed a lower median value of 19.4 ppb (14–32). Similarly, patients with abnormal FEF_{25–75%} had significantly (p < 0.001) higher values of FeNO [53.55 ppb (25–80)] than patients with normal FEF_{25–75%} [21.60 ppb (12–61)], as shown in table 2. Moreover, the sputum eosinophil

Table 2. Demographic, functional and biological characteristics of the patients according to normal or abnormal FEF_{25-75%}

	Abnormal FEF _{25-75%} (n = 110)	Normal FEF _{25-75%} (n = 290)	p
Age, years	27.9 (18.4–41.4)	31.15 (17.8–41.4)	n.s.
Gender F/M	66/44 (58/42)	160/130 (55/45)	n.s.
Allergy	14 (12.7)	28 (9.6)	n.s.
FVC, % predicted	98.87 (97.1–120.7)	100.37 (81.8–107.8)	n.s.
FEV ₁ , % predicted	98.51 (96.4–116.5)	99.44 (82.6–106.1)	n.s.
BHR, mg/ml	7.80 (0.10–16.00)	16.00 (0.10–16.00)	<0.001
FeNO, ppb	53.55 (25–80)	21.60 (12–61)	<0.001
Sputum eosinophils, %	9.86 (2.16–21.01)	1.21 (0.00–7.83)	<0.001

Data are expressed as medians (minimum–maximum) or n (%). n.s. = Not significant.

Table 3. Correlation coefficients between variables

	BHR		FeNO		Eosinophils	
	S	p	S	p	S	p
FEF _{25-75%} (% pred.)	0.270	<0.001	-0.660	<0.001	-0.752	<0.001
FEF _{25-75%} (z-score)	0.339	<0.001	-0.729	<0.001	-0.813	<0.001
BHR			-0.851	<0.001	-0.760	<0.001
FeNO					0.944	<0.001

S = Spearman's correlation coefficient; % pred. = % predicted.

Table 4. Cross tabulation between BHR and FEF_{25-75%} (categorized)

	FEF _{25-75%}	
	normal	abnormal
BHR		
Normal	166	10
Abnormal	124	100

With abnormal FEF_{25-75%}, the OR for BHR positivity was 13.38 (95% CI: 6.7–26.7, p < 0.001).

count in BHR-negative and normal-FEF_{25-75%} patients was significantly lower than that in BHR-positive and abnormal-FEF_{25-75%} patients [0.6 cells (0–3.1) in BHR-negative vs. 6.5 cells (0.0–21.0) in BHR-positive patients, p < 0.001; 1.2 cells (0.0–7.8) in normal-FEF_{25-75%} vs. 9.89 cells (2.1–21.0) in abnormal-FEF_{25-75%} patients, p < 0.001]. Of the BHR-positive and BHR-negative patients, 13.4 and

6.8%, respectively, were allergen sensitized, and this difference was statistically significant (χ^2 test, p = 0.03). Subjects with abnormal FEF_{25-75%} had an increased probability of being BHR positive (OR = 13.38; 95% CI: 6.7–26.7; p < 0.001) (table 4).

Discussion

In the present study, a cohort of subjects with asthma-like symptoms and normal FVC, FEV₁ and FEV₁/FVC showed a relationship between FEF_{25-75%} values and BHR to methacholine – the hallmark of bronchial asthma – and between FEF_{25-75%} values and markers of eosinophilic airway inflammation such as FeNO and sputum eosinophils. Moreover, patients with abnormal FEF_{25-75%}, which is considered a reliable marker of early airflow limitation [4–8], had higher FeNO and sputum eosinophil levels than patients with normal FEF_{25-75%}. We also pointed out that subjects with asthma-like symptoms and abnormal




Fig. 1. Overall patients' relationship between BHR and $FEF_{25-75\%}$ z-score. $S = 0.339$, $p < 0.001$.




Fig. 2. Overall patients' relationship between $FEF_{25-75\%}$ z-score and FeNO. $S = -0.729$, $p < 0.001$.




Fig. 3. Overall patients' relationship between $FEF_{25-75\%}$ z-score and sputum eosinophils. $S = -0.813$, $p < 0.001$.




Fig. 4. Overall patients' relationship between BHR and FeNO. $S = -0.851$, $p < 0.001$.

$FEF_{25-75\%}$ had a high probability of being BHR positive (OR = 13.38). These findings strengthen the hypothesis that early airflow limitation, expressed as abnormal $FEF_{25-75\%}$, is probably related to eosinophilic airway inflammation. In the literature, $FEF_{25-75\%}$ was validated as a marker able to predict high FeNO levels in asthmatic children [13] and correlated with FeNO in terms of per-

cent change in improvement after 6 weeks of inhaled corticosteroid treatment in controlled asthmatic children [29]. In addition, Rao et al. [30] observed that in children, a low $FEF_{25-75\%}$ associated with a normal FEV_1 is linked to increased asthma severity, systemic steroid use and asthma exacerbations. Using the percent change in $FEF_{25-75\%}$ from baseline might be helpful in identifying

bronchodilator responsiveness in asthmatic children with normal FEV₁ [30]. In our study, FEF_{25-75%}, expressed both as z-score and percent of predicted, is strongly related to sputum eosinophil and FeNO values in subjects with asthma-like symptoms. In addition, subjects with abnormal FEF_{25-75%} showed a higher number of sputum eosinophils and higher FeNO values than subjects with normal FEF_{25-75%}, suggesting that FEF_{25-75%} could be considered a sensitive spirometric marker associated with eosinophilic airway inflammation in newly diagnosed adult asthma cases with normal FEV₁ and FVC.

We found a marked correlation between FeNO and sputum eosinophils confirming previous reports on the capability of FeNO to reflect eosinophilic airway inflammation at mucosal and luminal levels [14, 31]. In particular, concerning this aspect, we point out that blockade of interleukin-5, a key cytokine in eosinophil differentiation/maturation in the bone marrow as well as in recruitment/activation at sites of allergic inflammation, was expected to deplete eosinophils and improve symptoms in subjects with asthma. Surprisingly, a humanized monoclonal antibody against interleukin-5 (mepolizumab) substantially reduced eosinophil levels in peripheral blood and sputum in relation to a reduction of asthma exacerbations but did not appear to have pharmacodynamic effects on FeNO levels [32, 33]. Taken together, these data suggest (1) that although targeting eosinophils can significantly reduce the rate of asthma exacerbations, the precise roles of eosinophils in the biology of asthma are still unclear, and (2) that FeNO is mainly dependent on epithelium-derived inducible NO synthase production, which could be influenced by different stimuli/triggers such as viruses and eosinophil-derived mediators in the airways [34]. Thus, FeNO might be considered a marker of asthmatic airway dysfunction not only related to airway eosinophilia.

FEF_{25-75%} has been found to correlate with functional imaging assessment of small airway function [35] as well as indices of ventilation heterogeneity, which are markers of peripheral airway function, obtained with multiple nitrogen washout in normal subjects [36] and with double-tracer gas single-breath washout in mild asthmatics [37]. FEF_{25-75%} percent of predicted has been demonstrated to correlate better with air trapping in asthmatic subjects than do FEV₁ percent of predicted and FEV₁/FVC percent of predicted [6]. Furthermore, in the archetypal small airways disease – that is, obliterative bronchiolitis – FEF_{25-75%} is considered the most sensitive functional marker of early diagnosis [38, 39]. Finally, a paper by Bergeron et al. [40] concerning airway remodelling

showed a significant reduction in the expression of smooth muscle α -actin in the small airways by analysing transbronchial biopsy specimens before and after 6 weeks of treatment with extra-fine inhaled corticosteroid. In fact, α -actin expression was correlated with improved FEF_{25-75%}, suggesting an association between FEF_{25-75%} values and histology. Thus, on the basis of all this evidence, we may speculate that in the present study, abnormal FEF_{25-75%} in symptomatic subjects with normal FEV₁ can be considered a marker of early airway obstruction without involvement of the proximal/central airways. Pisi et al. [41] suggested investigating small airway dysfunction in asthmatic patients with normal FEV₁ values by using an impulse oscillometry system as an alternative to spirometry.

In our population, abnormal FEF_{25-75%} was associated with an increased BHR as measured by OR, indicating that FEF_{25-75%} could be a simple and non-invasive marker of suspected BHR in patients with asthma-like symptoms and normal spirometric values. Small airways disease, assessed by peripheral airway resistance, has recently been associated with excessive bronchoconstriction in asthmatic patients [42]. Our data support the role of FEF_{25-75%} as a marker of early airway obstruction and as a risk factor for BHR positivity and severity in agreement with previous reports on allergic [43–45] and rhinitic subjects [10]; therefore, in clinical practice a more rational approach should also include measurements of FEF_{25-75%} [46]. In agreement with other authors, we suggest a combined approach towards asthma follow-up, involving clinical aspects, functional parameters (FEF_{25-75%}) and inflammatory biomarkers (FeNO) [46–48].

In the current study, a negative correlation between BHR and FeNO/sputum eosinophils has been shown; in addition, BHR-positive symptomatic subjects showed higher FeNO than BHR-negative subjects. BHR to non-specific bronchoconstrictor stimuli is a key feature of asthma and could be associated with the inflammatory process of the disease. Several studies have shown that BHR to indirect stimuli such as bradykinin, mannitol and adenosine is related to FeNO or eosinophilic inflammation [12, 49–51], whilst a relationship between BHR and direct stimuli such as methacholine and FeNO or eosinophilic inflammation exists [19, 52] but is expressed to a lesser extent [51, 53] or remains controversial [49, 50, 54, 55]. Finally, on the basis of the present data on FeNO in BHR-positive compared to BHR-negative patients, it can be postulated that FeNO might also be a marker potentially able to identify BHR-positive patients with new-onset asthma, and that the link between BHR and FeNO/

eosinophilic inflammation is strictly involved in the pathogenesis of early airflow limitation as detected in newly diagnosed adult asthma cases.

In this study, we also found a small number of subjects with asthma-like symptoms to have allergen sensitization (10.5%); in particular, the number of allergic subjects with positive BHR was significantly higher than that of allergic subjects with negative BHR. These results are in agreement with those of a previous study which demonstrated that the attributable fraction of new-onset asthma (at an age of 20–44 years) to atopy varied from 12 to 21%, indicating that only a relatively small proportion of new-onset asthma in adults is linked to atopy [56]. In addition, a study based on the Italian population (aged 20–44 years) showed that the prevalence of asthma and asthma-like symptoms has increased in the past 20 years, and that this increase has mainly been due to non-atopic subjects, suggesting that this trend might reflect changes in population exposures [57].

The clinical relevance of the present study is based on an adequate number of enrolled patients. Unfortunately, in this study, data concerning the clinical diagnosis of persistent/seasonal rhinitis were not collected in the medical records, and thus the authors were not able to correlate this major risk factor for asthma [58] with the analysed variables. Another limitation of this study is intrinsically connected with the study type (cross-sectional),

which does not estimate patients' progression; however, this limitation is well balanced by the large size of the chosen sample. An additional limitation might be the absence of post-bronchodilator data, even if reversibility testing is not mandatory for subjects with an $FEV_1 > 80\%$ of predicted. Despite the fact that the weak reproducibility of $FEF_{25-75\%}$ measurements represents one of the most important limitations for clinical use, we want to emphasize that the measure of $FEF_{25-75\%}$ is the index of early airflow limitation most widely available in routine practice for identifying new-onset asthmatics [59]. Finally, it might have been useful to have other measures of small airway function, such as an impulse oscillometry system, nitrogen washout and plethysmography; however, these tools have been unavailable in our own routine clinical practice.

In conclusion, the present study shows that abnormal $FEF_{25-75\%}$ might be considered an early functional marker of airflow limitation associated with eosinophilic inflammation and BHR in symptomatic subjects, suggesting a predictive role as a marker of newly diagnosed asthma.

Financial Disclosure and Conflicts of Interest

The authors declare no conflict of interest.

References

- 1 Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention, updated 2015. http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf.
- 2 Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC: Inflammation of small airways in asthma. *J Allergy Clin Immunol* 1997;100:44–51.
- 3 Perez T, Chanez P, Dusser D, Deviller P: Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. *Respir Med* 2013;107:1667–1674.
- 4 Ruppel G: *Manual of Pulmonary Function Testing*, ed 5. St. Louis, Mosby, 1991, pp 46–48.
- 5 Lipworth BJ, Clark DJ: Effects of airway calibre on lung delivery of nebulised salbutamol. *Thorax* 1997;52:1016–1023.
- 6 Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr, Szeffler SJ, Taussig L, Bacharier LB, Morgan W; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute: Forced expiratory flow between 25% and 75% of vital capacity and FEV_1 /forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV_1 values. *J Allergy Clin Immunol* 2010;126:527–534.e1–e8.
- 7 Lipworth B: Targeting the small airways asthma phenotype: if we can reach it, should we treat it? *Ann Allergy Asthma Immunol* 2013;110:233–239.
- 8 Ciprandi G, Capasso M, Tosca M, Salpietro C, Salpietro A, Marseglia G, La Rosa M: A forced expiratory flow at 25–75% value <65% of predicted should be considered abnormal: a real-world, cross-sectional study. *Allergy Asthma Proc* 2012;33:e5–e8.
- 9 Muñoz-López F, Ríos-Alcolea M: The interest of FEF_{25-75} in evaluating bronchial hyperresponsiveness with the methacholine test. *Allergol Immunopathol (Madr)* 2012;40:352–356.
- 10 Ciprandi G, Cirillo I: Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis. *J Allergy Clin Immunol* 2011;127:549; discussion 550–551.
- 11 Alberts WM, Ferris MC, Brooks SM, Goldman AL: The $FEF_{25-75\%}$ and the clinical diagnosis of asthma. *Ann Allergy* 1994;73:221–225.
- 12 Ricciardolo FL, Di Stefano A, Silvestri M, Van Schadewijk AM, Malerba M, Hiemstra PS, Sterk PJ: Exhaled nitric oxide is related to bronchial eosinophilia and airway hyperresponsiveness to bradykinin in allergen-induced asthma exacerbation. *Int J Immunopathol Pharmacol* 2012;25:175–182.
- 13 Ciprandi G, Tosca MA, Cirillo I, Lionetti E, Leonardi S, Miraglia Del Giudice M, La Rosa M, Salpietro A, Capasso M, Marseglia GL: Impaired FEF_{25-75} may predict high exhaled nitric oxide values in children with allergic rhinitis and/or asthma. *J Biol Regul Homeost Agents* 2012;26(suppl):S27–S33.
- 14 Ricciardolo FL: Revisiting the role of exhaled nitric oxide in asthma. *Curr Opin Pulm Med* 2014;20:53–59.

- 15 Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ: Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. *Thorax* 1998;53:91–95.
- 16 ElHalawani SM, Ly NT, Mahon RT, Amundson DE: Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. *Chest* 2003;124:639–643.
- 17 Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S: Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation test. *Thorax* 2005;60:383–388.
- 18 Ciprandi G, Tosca MA, Capasso M: Exhaled nitric oxide in children with allergic rhinitis and/or asthma: a relationship with bronchial hyperreactivity. *J Asthma* 2010;47:1142–1147.
- 19 Tossa P, Paris C, Zmirou-Navier D, Demange V, Acouetey DS, Michaely JP, Bohadana A: Increased in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices. *Am J Respir Crit Care Med* 2010;182:738–744.
- 20 Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. *Eur Respir J* 2005;26:948–968.
- 21 Skin tests used in type I allergy testing. Position paper. Sub-Committee on Skin Tests of the European Academy of Allergology and Clinical Immunology. *Allergy* 1989;44(suppl 10):1–59.
- 22 Clausen JL, Coates AL, Quanjer PH: Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. *Eur Respir J* 1997;10:1205–1206.
- 23 Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the Global Lung Function 2012 equations. *Eur Respir J* 2012;40:1324–1343.
- 24 American Thoracic Society: Guidelines for methacholine and exercise challenge testing. *Am J Respir Crit Care Med* 1999;161:309–329.
- 25 ATS/ERS recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005;171:912–930.
- 26 Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C, Malerba M: Reference values for exhaled nitric oxide (reveno) study. *Respir Res* 2006;7:94.
- 27 Malerba M, Ricciardolo F, Radaeli A, Torregiani C, Ceriani L, Mori E, Bontempelli M, Tantucci C, Grassi V: Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects. *Thorax* 2006;61:129–133.
- 28 Balbi B, Pignatti P, Corradi M, Baiardi P, Bianchi L, Brunetti G, Radaeli A, Moscato G, Mutti A, Spavanello A, Malerba M: Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. *Eur Respir J* 2007;30:769–781.
- 29 Yoon JY, Woo SI, Kim H, Sun YH, Hahn YS: Fractional exhaled nitric oxide and forced expiratory flow between 25% and 75% of vital capacity in children with controlled asthma. *Korean J Pediatr* 2012;55:330–336.
- 30 Rao DR, Gaffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Phipatanakul W: The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. *J Asthma* 2012;49:586–592.
- 31 Cirillo I, Ricciardolo FLM, Medusei G, Signori A, Ciprandi G: Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. *Int Arch Allergy Immunol* 2013;160:322–328.
- 32 Pavord ID, Korn S, Howarth P, Bleeker ER, Buhl R, Keene ON, Ortega H, Chanez P: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012;380:651–659.
- 33 Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradling P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009;360:973–984.
- 34 Ricciardolo FLM, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. *Physiol Rev* 2004;84:731–765.
- 35 Jain N, Covar RA, Gleason MC, Newell JD Jr, Gelfand EW, Spahn JD: Quantitative computed tomography detects peripheral airway disease in asthmatic children. *Pediatr Pulmonol* 2005;40:211–218.
- 36 Verbanck S, Kerckx Y, Schuermans D, Vincken W, Paiva M, Van Mueylem A: Effect of airways constriction on exhaled nitric oxide. *J Appl Physiol* (1985) 2008;104:925–930.
- 37 Singer F, Abbas C, Yammine S, Casaulta C, Frey U, Latzin P: Abnormal small airways function in children with mild asthma. *Chest* 2014;145:492–499.
- 38 Patterson GM, Wilson S, Whang JL, Harvey J, Agacki K, Patel H, Theodore J: Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second. *J Heart Lung Transplant* 1996;15:175–181.
- 39 Sritipiyawan S, Keens TG, Horn MV, Starnes VA, Woo MS: What are the best pulmonary function test parameters for early detection of post-lung transplant bronchiolitis obliterans syndrome in children? *Pediatr Transplant* 2003;7:200–203.
- 40 Bergeron C, Hauber HP, Gotfried M, Newman K, Dhanda R, Servi RJ, Ludwig MS, Hamid Q: Evidence of remodelling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. *J Allergy Clin Immunol* 2005;116:983–989.
- 41 Pisi R, Tzani P, Aiello M, Martinelli E, Marangio E, Nicolini G, Olivieri D, Chetta A: Small airway dysfunction by impulse oscillometry in asthmatic patients with normal forced expiratory volume in the 1st second values. *Allergy Asthma Proc* 2013;34:e14–e20.
- 42 Alfieri V, Aiello M, Pisi R, Tzani P, Mariani E, Marangio E, Olivieri D, Nicolini G, Chetta A: Small airway dysfunction is associated to [sic] excessive bronchoconstriction in asthmatic patients. *Respir Res* 2014;15:86.
- 43 Cirillo I, Klersy C, Marseglia GL, Vizzaccaro A, Pallestrini E, Tosca M, Ciprandi G: Role of FEF_{25%–75%} as a predictor of bronchial hyperreactivity in allergic patients. *Ann Allergy Asthma Immunol* 2006;96:692–700.
- 44 Ciprandi G, Cirillo I, Tosca MA, Vizzaccaro A: Bronchial hyperreactivity and spirometric impairment in polysensitized patients with allergic rhinitis. *Clin Mol Allergy* 2004;2:3.
- 45 van der Wiel E, Postma DS, van der Molen T, Schiphof-Godart L, Ten Hacken NH, van den Berge M: Effects of small airway dysfunction on the clinical expression of asthma: a focus on asthma symptoms and bronchial hyperresponsiveness. *Allergy* 2014;69:1681–1688.
- 46 Contoli M, Santus P, Papi A: Small airway disease in asthma: pathophysiological and diagnostic considerations. *Curr Opin Pulm Med* 2015;21:68–73.
- 47 Leblanc A, Botelho C, Coimbra A, da Silva JP, de Castro ED, Cernadas JR: Assessment of asthma control: clinical, functional and inflammatory aspects. *Eur Ann Allergy Clin Immunol* 2013;45:90–96.
- 48 Contoli M, Kraft M, Hamid Q, Bousquet J, Rabe KF, Fabbri LM, Papi A: Do small airway abnormalities characterize asthma phenotypes? In search of proof. *Clin Exp Allergy* 2012;42:1150–1160.
- 49 Roisman GL, Lacroque JG, Desmazes-Dufeu N, Carré C, Le Cae A, Dusser DJ: Airway responsiveness to bradykinin is related to eosinophilic inflammation in asthma. *Am J Respir Crit Care Med* 1996;153:381–390.
- 50 Sverrild A, Porsbjerg C, Thomsen SF, Backer V: Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: a random-sample population study. *J Allergy Clin Immunol* 2010;126:952–958.
- 51 Perzanowski MS, Yoo Y: Exhaled nitric oxide and airway hyperresponsiveness to adenosine 5'-monophosphate and methacholine in children with asthma. *Int Arch Allergy Immunol* 2015;166:107–113.
- 52 Muñoz X, Sanchez-Vidaurre S, Roca O, Torres F, Morell F, Cruz MJ: Bronchial inflammation and hyperresponsiveness in well controlled asthma. *Clin Exp Allergy* 2012;42:1321–1328.

- 53 Porsbjerg C, Brannan JD, Anderson SD, Backer V: Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. *Clin Exp Allergy* 2008;38:43–50.
- 54 Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V: Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. *Am J Respir Crit Care Med* 1998;157:4–9.
- 55 Imaoka H, Gauvreau GM, Watson RM, Strinich T, Obminksi GL, Howie K, Killian KJ, O'Byrne PM: Sputum inflammatory cells and allergen-induced airway responses in allergic asthmatic subjects. *Allergy* 2011;66:1075–1080.
- 56 Antó JM, Sunyer J, Basagaña X, Garcia-Esteban R, Cerveri I, de Marco R, Heinrich J, Janson C, Jarvis D, Kogevinas M, Kuenzli N, Leynaert B, Svanes C, Wjst M, Gislason T, Burney P: Risk factors of new-onset asthma in adults: a population-based international cohort study. *Allergy* 2010;65:1021–1030.
- 57 de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O, Braggion M, Bugiani M, Casali L, Cazzoletti L, Cerveri I, Fois AG, Girardi P, Locatelli F, Marcon A, Marinoni A, Panico MG, Pirina P, Villani S, Zanolin ME, Verlato G; GEIRD Study Group: Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. *Eur Respir J* 2012;39:883–892.
- 58 Guerra S, Sherrill DL, Martinez FD, Barbee RA: Rhinitis as an independent risk factor for adult onset asthma. *J Allergy Clin Immunol* 2002;109:419–425.
- 59 Linares Passerini M, Meyer Peirano R, Contreras Estay I, Delgado Becerra I, Castro-Rodriguez JA: Utility of bronchodilator response for asthma diagnosis in Latino preschoolers. *Allergol Immunopathol (Madr)* 2014;42:553–559.